12.03.2012 • NewsIndonesiaEmery Oleochemicalsjoint venture

Emery Oleochemicals Plans Expansion

Emery Oleochemicals, a manufacturer of plastic additives made mostly from palm oil, may sharply boost its fundraising as it plans to expand globally and explore tie-ups with companies in top palm oil producer Indonesia, its chief executive said.

The Thai-Malaysian joint venture is reviewing its 480 million ringgit ($158.9 million) Islamic bond plan to fuel its growth to meet higher demand for oleochemicals, used in soaps and pharmaceuticals, Kongkrapan Intarajang said on Tuesday.

"Growth is going to be bigger than expected. We hope to announce something in the second quarter," Intarajang told Reuters in an interview on the sidelines of the Bursa Malaysia Palm Oil Conference.

Funding could come from a combination of sources and financial instruments.

A joint venture between the plantation division of Malaysia's Sime Darby, the world's largest palm oil firm by estate holdings, and the international arm of Thailand's PTT Global Chemical, Emery Oleochemicals is headquartered in Malaysia.

The firm operates about one million tonnes of oleochemical capacity across Europe, the United States and Asia, making it one of the biggest producers of specialty chemicals used also in cosmetics and soaps.

The Islamic bonds, which were supposed to be sold in the second quarter of this year, would finance the construction of three Malaysian plants with a combined annual capacity of roughly 60,000 to 80,000 tonnes.

One of the plants, with a yearly capacity of 20,000 tonnes, will come online in the second quarter of 2012 and will produce green polymer additives that is used to manufacture plastics, Intarajang said.

Indonesia also offers opportunities as it recently slashed its export taxes for processed palm oil, to help refiners and processors tap greater margins.

"It is not only about the tax but Indonesia has more feedstock supply. We are looking at good Indonesian partners and we are still at the exploratory phase of talks," Intarajang said.

"We could also be looking at the Malaysian plantation companies with holdings in Indonesia," he added.

Emery's expansion comes as Asian demand for home and personal care products, which use oleochemicals, rises in tandem with incomes and resilient economic growth.

Competitors for Emery include IOI Corp and KL Kepong, Malaysia's second- and third-largest palm oil firms and Wilmar International, the world's top listed palm oil processor.

Backed with plantations, these firms have been aggressive at expanding oleochemical capacity or acquiring smaller factories to grow the business.

KL Kepong bought a 150,000 tonne per year fatty acids facility in Germany from British oleochemical maker Croda International in 2010. Wilmar snapped up Malaysian oleochemicals firm Natural Oleochemicals in the same year.

"More consolidation will happen but it will be more selective compared to the 2007-2008 financial crisis that created the environment for more mergers and acquisition," Intarajang said.

 

 

 

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.